Literature DB >> 30155725

[Ten key messages regarding embolic stroke of undetermined source and cryptogenic stroke].

P Böttger1,2, M Grond3,4, H Lemm5, M Buerke5,6.   

Abstract

Cryptogenic stroke is a cerebral infarction where no source of cardioembolic events, no microangiopathy with lacunar infarcts, and no macroangiopathy with high-grade stenosis of the cerebral arteries can be detected. However, cryptogenic stroke is not operationally defined. The new concept of the embolic stroke of undetermined source (ESUS) is defined as a nonlacunar stroke in cerebral imaging and exclusion of significant stenosis of the cerebral arteries by angiographic or ultrasound techniques. Cardiac embolic sources must be excluded by ECG monitoring and echocardiography. At the moment, secondary prevention in patients with ESUS is performed with acetylsalicylic acid. The question of whether non-vitamin K oral anticoagulants (NOAK) are effective in these patients for secondary prevention is currently being investigated in randomized trials. The acute treatment of cryptogenic stroke/ESUS does not differ from other stroke subtypes because the stroke etiology is often not known initially, but can be identified during the course of treatment in the stroke unit.

Entities:  

Keywords:  Acetylsalicylic acid; Cerebral arteries; Oral anticoagulants; Secondary prevention; Stenosis

Mesh:

Substances:

Year:  2018        PMID: 30155725     DOI: 10.1007/s00063-018-0470-6

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  33 in total

Review 1.  Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update.

Authors:  Robert G Hart; Luciana Catanese; Kanjana S Perera; George Ntaios; Stuart J Connolly
Journal:  Stroke       Date:  2017-03-06       Impact factor: 7.914

2.  Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study.

Authors:  Ralph L Sacco; Shyam Prabhakaran; J L P Thompson; Amy Murphy; Robert R Sciacca; Bruce Levin; J-P Mohr
Journal:  Cerebrovasc Dis       Date:  2006-03-27       Impact factor: 2.762

3.  Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study.

Authors:  P L Kolominsky-Rabas; M Weber; O Gefeller; B Neundoerfer; P U Heuschmann
Journal:  Stroke       Date:  2001-12-01       Impact factor: 7.914

4.  Embolic strokes of undetermined source in the Athens stroke registry: a descriptive analysis.

Authors:  George Ntaios; Vasileios Papavasileiou; Haralambos Milionis; Konstantinos Makaritsis; Efstathios Manios; Konstantinos Spengos; Patrik Michel; Konstantinos Vemmos
Journal:  Stroke       Date:  2014-11-06       Impact factor: 7.914

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.

Authors:  Jeffrey L Saver; John D Carroll; David E Thaler; Richard W Smalling; Lee A MacDonald; David S Marks; David L Tirschwell
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

7.  Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study.

Authors:  Steven C Cramer; Guy Rordorf; Jeffrey H Maki; Larry A Kramer; James C Grotta; W Scott Burgin; Judith A Hinchey; Curtis Benesch; Karen L Furie; Helmi L Lutsep; Ellen Kelly; W T Longstreth
Journal:  Stroke       Date:  2003-12-04       Impact factor: 7.914

8.  Autopsy prevalence of intracranial atherosclerosis in patients with fatal stroke.

Authors:  Mikael Mazighi; Julien Labreuche; Fernando Gongora-Rivera; Charles Duyckaerts; Jean-Jacques Hauw; Pierre Amarenco
Journal:  Stroke       Date:  2008-02-28       Impact factor: 7.914

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  Embolic strokes of undetermined source: the case for a new clinical construct.

Authors:  Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly
Journal:  Lancet Neurol       Date:  2014-04       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.